Fredun Pharmaceuticals standalone net profit rises 85.03% in the December 2022 quarter

With a market valuation of Rs. 577.91 Cr., Fredun Pharmaceuticals Ltd. is a small-cap company engaged in the pharmaceutical industry.

Multibagger stock hits 5% upper circuit as Board signs contracts worth ₹90 Cr

Fredun Pharmaceuticals standalone net profit rises 71.20% in the September 2022 quarter

Fredun Pharmaceuticals standalone net profit rises 121.69% in the September 2021 quarter

Fredun Pharmaceuticals manufactures and distributes pharmaceutical products.

Fredun Pharmaceuticals receives prestigious award; Stock zooms 6%

Fredun Pharmaceuticals standalone net profit rises 725.00% in the June 2021 quarter

Fredun Pharmaceuticals reports standalone net profit of Rs 0.73 crore in the March 2021 quarter

Fredun Pharmaceuticals standalone net profit rises 31.37% in the December 2020 quarter

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Financials growth has been moderate for a few years

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Fredun Pharmaceuticals Ltd. is a pharmaceutical company engaged in the manufacturing and sale of pharmaceutical formulations. The Company’s products include I V fluids, disposable syringes, infusion sets, surgical gloves and cottons etc.